PMID- 28827806
OWN - NLM
STAT- MEDLINE
DCOM- 20171013
LR  - 20240216
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 8
DP  - 2017
TI  - The association between observed mobility and quality of life in the near 
      elderly.
PG  - e0182920
LID - 10.1371/journal.pone.0182920 [doi]
LID - e0182920
AB  - INTRODUCTION: Chronic diseases associated with aging, such as arthritis, 
      frequently cause reduced mobility, pain and diminished quality of life. To date, 
      research on the association between mobility and quality of life has primarily 
      focused in the elderly; hence, much less is known about this association in the 
      near elderly. This cross-sectional study aimed to assess the association between 
      mobility and quality of life measures in the near elderly. METHODS: A prospective 
      observational study of persons aged 50-69 years was conducted. The primary 
      endpoint was quality of life measured by EQ-5D-5L, and the primary explanatory 
      variable was observed mobility assessed using the 6-minute walk distance (6MWD). 
      We applied regression models controlling for demographic, health status and other 
      factors to evaluate the association between 6MWD and EQ-5D-5L. RESULTS: Of the 
      183 participants analyzed in the study, 37% were male and the average age was 
      59.8 years. After adjusting for differences in demographic characteristics and 
      health status, EQ-5D-5L-based utility values were 0.046 points (p<0.001), or 5.2% 
      (95% CI: 2.7% to 7.8%), higher on average for individuals with 100 meters longer 
      6MWD. Holding constant the mobility-specific component of EQ-5D-5L, we still 
      found that walking an additional 100 meters was associated with an EQ-5D-5L 
      utility value that was 0.029 points (p<0.001), or 3.5% (95% CI: 1.7% to 5.5%), 
      higher than the average participant. Among persons with arthritis, the 
      association between 6MWD and EQ-5D-5L was slightly stronger. CONCLUSIONS: Near 
      elderly persons with better mobility had higher quality of life. Diseases that 
      decrease mobility, such as arthritis, are likely to have a significant impact on 
      quality of life.
FAU - Shafrin, Jason
AU  - Shafrin J
AUID- ORCID: 0000-0001-5777-2077
AD  - Precision Health Economics, Los Angeles, California, United States of America.
FAU - Sullivan, Jeff
AU  - Sullivan J
AD  - Precision Health Economics, Los Angeles, California, United States of America.
FAU - Goldman, Dana P
AU  - Goldman DP
AD  - Schaeffer Center for Health Policy and Economics, University of Southern 
      California, Los Angeles, California, United States of America.
FAU - Gill, Thomas M
AU  - Gill TM
AD  - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, 
      United States of America.
LA  - eng
GR  - K07 AG043587/AG/NIA NIH HHS/United States
GR  - P30 AG021342/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
DEP - 20170821
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Movement
MH  - Prospective Studies
MH  - *Quality of Life
PMC - PMC5572211
COIS- Competing Interests: I have read the journal's policy and the authors of this 
      manuscript have the following competing interests: Jason Shafrin and Jeff 
      Sullivan are employees of Precision Health Economics. Dana Goldman is a 
      consultant to Precision Health Economics and holds equity in the firm. Precision 
      Health Economics is a consultancy to the health insurance and life science 
      industries. Thomas M. Gill has received grant funding for research outside of 
      this study from the National Institute of Health. The study and manuscript 
      development was sponsored by Sanofi. http://en.sanofi.com/index.aspx This does 
      not alter our adherence to PLOS ONE policies on sharing data and materials. Rich 
      Toselli, employee of Sanofi contributed to the study design and John Chia, 
      employee of Sanofi contributed to data review. Sanofi reviewed the final version 
      of the manuscript for medical accuracy, but did not take part in the writing of 
      the manuscript.
EDAT- 2017/08/23 06:00
MHDA- 2017/10/14 06:00
PMCR- 2017/08/21
CRDT- 2017/08/23 06:00
PHST- 2017/03/03 00:00 [received]
PHST- 2017/07/26 00:00 [accepted]
PHST- 2017/08/23 06:00 [entrez]
PHST- 2017/08/23 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
PHST- 2017/08/21 00:00 [pmc-release]
AID - PONE-D-17-08604 [pii]
AID - 10.1371/journal.pone.0182920 [doi]
PST - epublish
SO  - PLoS One. 2017 Aug 21;12(8):e0182920. doi: 10.1371/journal.pone.0182920. 
      eCollection 2017.